big upgrades after earnings $
Seeking Alpha By: Brian Nichols 10/14/13
Pimavanserin: The Most Underestimated Blockbuster In Biotechnology
The bottom line is that as time passes, expect estimates to rise quickly for pima, which will then drive the valuation for Acadia. The current market potential for pima simply does not reflect the valuation of the PDP indication let alone ADP and Schzo. Therefore, unprecedented gains are likely. And for those of you hoping for a buyout or a substantial partnership, I'd cross your fingers and pray that management does not yet
entertain such offers. Due to the disruptive nature of pima, many leading pharmaceutical companies are going to lose billions because of pima, which means Acadia is likely already speaking with or is being assessed by a handful of large companies. However, this is a company that simply has too much upside for a 100% premium right now, and over the next year as peak sales estimate rise, you will see that any price under $50 is cheap
haha hope u bought.
Adam Feuerstein @adamfeuerstein 17m
$ACAD - None of the docs on Cowen panel taking place right now are slamming pimvanserin, according to a source on the scene.
just checked and they haven't sold a share. If Bakers Paid $50 Million for ACAD I'm In.
Facebook price target upped to $62 by Macquarie
SAN FRANCISCO (MarketWatch) - Macquarie on Thursday raised its price target for Facebook Inc. FB -2.11% to $62 from $49, based on the social network's momentum in mobile ads. "Facebook continues to gain traction with its efforts to monetize the mobile user base, with new statistics on mobile app install ads suggesting that growth remains strong and could generate upside to mobile ad revenue for the third quarter," analyst Ben Schachter said in a note